Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: a SEER database analysis

Bei, Yanping; Xue, Chen; Raturi, Vijay Parshuram; Liu, Kaitai; Ye, Shuang; Xu, Qian; Lu, Miaozhen

doi:10.1007/s40520-020-01517-z

Cited by 11 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer. Lung cancer is the most common cancer in the world and the leading cause of cancer death (123), which has an overall 5-year survival rate of ~15% (124). Despite advances in treatment, progressive NSCLC still severely limits survival and requires new therapeutic compounds (125).…”

Section: Potential Role Of Art In Human Malignanciesmentioning

confidence: 99%

Progress on the study of the anticancer effects of artesunate (Review)

et al. 2021

View full text Add to dashboard Cite

Artesunate (ART) is a derivative of artemisinin that is extracted from the wormwood plant Artemisia annua. ART is an antimalarial drug that has been shown to be safe and effective for clinical use. In addition to its antimalarial properties, ART has been attracting attention over recent years due to its reported inhibitory effects on cancer cell proliferation, invasion and migration. Therefore, ART has a wider range of potential clinical applications than first hypothesized. The aim of the present review was to summarize the latest research progress on the possible anticancer effects of ART, in order to lay a theoretical foundation for the further development of ART as a therapeutic option for cancer. Contents1. Introduction 2. Source and activity of ART 3. Anticarcinogenic mechanism of ART 4. Potential role of ART in human malignancies 5. Summary and perspectives

show abstract

Section: Potential Role Of Art In Human Malignanciesmentioning

confidence: 99%

Progress on the study of the anticancer effects of artesunate (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The effectiveness and success of surgical treatment in advanced-stage lung cancer patients, especially those over eighty years old, remains a controversial topic in light of current research and clinical practices. [3][4][5] This study aims to comprehensively evaluate the factors affecting surgical success in elderly lung cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Lobectomy and pneumonectomy in patients over 70 years of age for the treatment of lung cancer: evaluation of surgical outcomes

Buz,

Kahraman,

Özdemir

et al. 2024

Anatolian Current Medical Journal

View full text Add to dashboard Cite

Aims: The primary aim of this study is to evaluate the surgical outcomes of lobectomy and pneumonectomy operations performed due to lung cancer in individuals aged 70 and above, and to analyze the factors influencing these outcomes. Methods: This retrospective study covers lobectomy and pneumonectomy operations performed on 103 lung cancer patients over the age of 70, from January 2018 to December 2021. A dataset was created including patients’ demographic information, smoking status, comorbidities, results of pulmonary function tests and echocardiography, preoperative complete blood count, and serum albumin levels, and these data were analyzed. Results: The average age of the patients was 73.3; 83.5% were male, and 16.5% were female. The complication rate was 47.6%, and the 30-day surgical mortality rate was 8.7%. Patients with a high American Society of Anesthesiologists (ASA) score had higher rates of complications and mortality (p=0.015). Low preoperative serum albumin (p=0.017) and hemoglobin (p=0.026) levels were associated with an increased risk of complications. Postoperative outcomes between Video Assisted Thoracoscopic Surgery (VATS) and thoracotomy were found to be similar. Conclusion: The study demonstrates that in elderly lung cancer surgery, comorbidities and preoperative nutritional status are decisive factors affecting surgical outcomes. Preoperative albumin and hemoglobin levels emerge as significant indicators in assessing the risk of postoperative complications. VATS and thoracotomy are surgical techniques with similar safety and efficacy profiles.

show abstract

“…Over the last decade, SABR has gained an increasing popularity, particularly among older patients. In the United States and European countries, RT has replaced surgery as the most commonly used treatment modality for early-stage NSCLC in patients aged ≥ 80 years [4][5][6]. However, whether radiotherapy or surgery has a better impact on the treatment for such patients remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Surgery versus radiotherapy in octogenarians with stage Ia non‑small cell lung cancer: propensity score matching analysis of the SEER database

Liu

Zhang

et al. 2022

BMC Pulm Med

View full text Add to dashboard Cite

Objectives To compare overall survival (OS) and cancer-specific survival (CSS) outcomes of surgery with radiotherapy in octogenarians with stage Ia non-small cell lung cancer (NSCLC). Materials and methods Patients aged ≥ 80 years with clinical stage Ia (T1N0M0) NSCLC between 2012 and 2017 were identified from the population-based Surveillance, Epidemiology, and End Results (SEER) database. Patients were assigned into surgery and radiotherapy groups. Multivariate Cox regression analysis was used to identify survival-associated factors. Treatment groups were adjusted by propensity score matching (PSM) analysis while OS and CSS outcomes were compared among groups by Kaplan–Meier analysis. Results A total of 1641 patients were identified, with 46.0% in the surgical group and 54.0% in the radiotherapy group. Compared to surgery, radiotherapy-treated patients were older, later diagnosed, had more often unmarried, more squamous cell carcinoma, more unknown grade and increased tumor sizes. Radiotherapy was associated with a significantly worse OS, compared to surgery (hazard ratio 2.426; 95% CI 2.003–2.939; P < .001). After PSM, OS (P < 0.001) and CSS (P < 0.001) were higher in the surgery group. The 1-, 3-, and 5-year OS rates of surgical and radiotherapy group were 90.0%, 76.9%, 59.9%, and 86.0%, 54.3%, 28.0%, respectively. The 1-, 3-, and 5-year CSS rates of surgical and radiotherapy group were 94.5%, 86.1%, 78.0% and 90.7%, 74.5%, 61.0%, respectively. There were no survival differences between the matched surgery without lymph node examination (LNE) and radiotherapy group, as well as between the matched surgery and radiotherapy who were recommended but refused surgery group. Conclusions In octogenarians with stage Ia NSCLC, surgery with lymph node dissection offers better OS and CSS outcomes than radiotherapy.

show abstract

Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: a SEER database analysis

Cited by 11 publications

References 33 publications

Progress on the study of the anticancer effects of artesunate (Review)

Progress on the study of the anticancer effects of artesunate (Review)

Lobectomy and pneumonectomy in patients over 70 years of age for the treatment of lung cancer: evaluation of surgical outcomes

Surgery versus radiotherapy in octogenarians with stage Ia non‑small cell lung cancer: propensity score matching analysis of the SEER database

Contact Info

Product

Resources

About